MedTrace Logo

Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19

NCT04344457 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-07-01

No results posted yet for this study

Summary

Currently there are no US Food and Drug Administration (FDA)-approved drugs specifically for the treatment of patients with COVID-19. At present, clinical management includes infection prevention and control measures, as well as supportive care, including supplementary oxygen and mechanical ventilatory support when indicated. An array of drugs approved for other indications as well as several investigational drugs are being studied in several hundred clinical trials that are underway across the globe; however, currently there are no clinical trials available to patients in Arizona.

This study will determine if a specific drug cocktail can improve clinical outcomes in patients with confirmed Mild SARS-CoV-2

Conditions

Interventions

DRUG

Hydroxychloroquine

200 mg PO BID 7 days

DRUG

Indomethacin

50 mg PO TID 14 Days

DRUG

Zithromax Oral Product

500 mg PO QD 3 Days

Sponsors & Collaborators

  • Athena Medical Group

    collaborator UNKNOWN

  • Perseverance Research Center, LLC

    lead OTHER

Principal Investigators

  • Teresa Gaither, NP · Athena Medical Group

  • Nicole C. Hank, PhD, MCR, MHSM · Perseverance Research Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-16
Primary Completion
2020-06-20
Completion
2020-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04344457 on ClinicalTrials.gov